drugset
drugset / Trial / NCT05770466

Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.

NCT05770466 ↗

Phase 3 Completed 134 enrolled National Taiwan University Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the efficacy of subcutaneous ropeginterferon alfa 2b ( P1101combined with standard of care (SOC) compared with standard care alone in hospitalized adults with moderate COVID 19.

Timeline

Start
2022-04-01
Primary completion
2022-12-21
Completion
2023-01-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ropeginterferon alfa-2b Protein / enzyme biologic 250 ug Subcutaneous

Indications

COVID-19